Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RIMABOTULINUMTOXINB vs RIPRETINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RIMABOTULINUMTOXINB vs RIPRETINIB: Safety Overview

Metric RIMABOTULINUMTOXINB RIPRETINIB
Total FAERS Reports 176 4,432
Deaths Reported 38 465
Death Rate 21.6% 10.5%
Hospitalizations 35 948
Average Patient Age 59.0 yrs 66.8 yrs
% Female Patients 68.6% 45.3%
FDA Approval Date N/A May 15, 2020
Manufacturer Solstice Neurosciences, LLC Deciphera Pharmaceuticals, LLC
Route INTRAMUSCULAR ORAL
Marketing Status N/A Prescription